Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer
Top Cited Papers
Open Access
- 28 March 2002
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 346 (13), 975-980
- https://doi.org/10.1056/nejmoa012385
Abstract
Abdominal surgery for cancer carries a high risk of venous thromboembolism, but the optimal duration of postoperative thromboprophylaxis is unknown. We conducted a double-blind, multicenter trial in which patients undergoing planned curative open surgery for abdominal or pelvic cancer received enoxaparin (40 mg subcutaneously) daily for 6 to 10 days and were then randomly assigned to receive either enoxaparin or placebo for another 21 days. Bilateral venography was performed between days 25 and 31, or sooner if symptoms of venous thromboembolism occurred. The primary end point with respect to efficacy was the incidence of venous thromboembolism between days 25 and 31. The primary safety end point was bleeding during the three-week period after randomization. The patients were followed for three months. The intention-to-treat analysis of efficacy included 332 patients. The rates of venous thromboembolism at the end of the double-blind phase were 12.0 percent in the placebo group and 4.8 percent in the enoxaparin group (P=0.02). This difference persisted at three months (13.8 percent vs. 5.5 percent, P=0.01). Three patients in the enoxaparin group and six in the placebo group died within three months after surgery. There were no significant differences in the rates of bleeding or other complications during the double-blind or follow-up periods. Enoxaparin prophylaxis for four weeks after surgery for abdominal or pelvic cancer is safe and significantly reduces the incidence of venographically demonstrated thrombosis, as compared with enoxaparin prophylaxis for one week.Keywords
This publication has 20 references indexed in Scilit:
- Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxisBritish Journal of Surgery, 2003
- Prevention of Venous ThromboembolismChest, 2001
- Cost-Effectiveness of Prolonged Administration of a Low Molecular Weight Heparin for the Prevention of Deep Venous Thrombosis Following Total Hip ReplacementValue in Health, 1999
- Efficacy and Safety of Prolonged Thromboprophylaxis with a Low Molecular Weight Heparin (Dalteparin) after Total Hip Arthroplasty— The Danish Prolonged Prophylaxis (DaPP) StudyThrombosis Research, 1998
- Efficacy and safety of enoxaparinversus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessmentBritish Journal of Surgery, 1997
- Low-Molecular-Weight Heparin (Enoxaparin) as Prophylaxis against Venous Thromboembolism after Total Hip ReplacementNew England Journal of Medicine, 1996
- Incidence of venous thromboembolism verified by necropsy over 30 years.BMJ, 1991
- Deep venous thrombosis: a continuing problem.BMJ, 1988
- A 30-year survey of pulmonary embolism verified at autopsy: An analysis of 1274 surgical patientsBritish Journal of Surgery, 1985
- Venous thrombosis and pulmonary embolism. A clinico-pathological study in injured and burned patientsBritish Journal of Surgery, 1961